These updated, evidence-based recommendations are intended to help physicians caring for patients with BS.
These updated data-derived and consensus-derived recommendations will help rheumatologists to manage patients with SSc in an evidence-based way. These recommendations also give directions for future clinical research in SSc.
S3 Guideline for the treatment of psoriasis vulgaris, update – Short version part 2 – Special patient populations and treatment situations
The German guideline for the treatment of psoriasis vulgaris was updated using GRADE methodology. The guideline is based on a systematic literature review completed on December 1, 2016, and on a formal consensus and approval process.
European S3-Guideline on the systemic treatment of psoriasis vulgaris - Update Apremilast and Secukinumab - EDF in cooperation with EADV and IPC.
In addition to the interventions discussed in the update, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) approved apremilast and secukinumab as new treatment options for psoriasis.
This guideline will therefore provide advice and rationale for health professionals in making choices and decisions in the management of this disease.
BSR and BHPR guideline for the prescription and monitoring of non-biologic disease-modifying anti-rheumatic drugs
The purpose of this guideline is to provide up-to-date, evidence-based recommendations for the safe use of non-biologic DMARDs in adults (>16 years old).
British Association of Dermatologists’ guidelines for the care of patients with actinic keratosis 2017
The overall objective of the guideline is to provide up-to-date, evidence-based recommendations for the management of actinic keratosis (AK).
British Association of Dermatologists’ guidelines for the investigation and management of generalized pruritus in adults without an underlying dermatosis, 2018
The overall objective of the guidelines is to provide up-todate, evidence-based recommendations on the investigation and management of secondary pruritus without underlying skin disorder and generalized pruritus of unknown origin (GPUO) in adults...
The overall objective of the guideline is to provide up-to-date, evidence-based recommendations for the management of pemphigus vulgaris (PV).
This guideline provides advice at all stages of the patient’s pathway of care, from primary prevention to early recognition, treatment and follow up.